Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, recently announced that Colin Hislop, M.D. has been promoted to chief medical officer. Dr. Hislop replaces James E. Pennington, M.D., who will continue to serve as the company’s senior clinical fellow.
Dr. Hislop has more than 15 years of drug development expertise in various areas, including cardiovascular‚ endocrinology‚ allergy/asthma and infectious disease. Prior to joining Anthera Pharmaceuticals‚ Dr. Hislop served as the vice president of clinical development for Peninsula Pharmaceuticals‚ Inc. where he oversaw three global development programs for Peninsula’s anti-infective product portfolio.
Prior to the announcement, Dr. Hislop has served as Anthera’s senior vice president of cardiovascular products since 2005, where he was the development leader for the company’s first product, Ranexa® (ranolazine), and championed the NDA efforts for this cardiovascular compound.
Earlier in his career, Dr. Hislop worked for seven years at Proctor and Gamble as the worldwide clinical development manager for the company’s osteoporosis drug, Actonel® (risedronate sodium). He also worked for Eli Lilly and Company in the United Kingdom as a medical advisor for the endocrinology group. Dr. Hislop earned his B.Sc. from University of Surrey in Medical Biochemistry and an M.D., B.S. from the University of London.
For additional information, please visit the company’s website at www.anthera.com.
Let us hear your thoughts below: